BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 20161759)

  • 1. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung.
    Yuan P; Kadara H; Behrens C; Tang X; Woods D; Solis LM; Huang J; Spinola M; Dong W; Yin G; Fujimoto J; Kim E; Xie Y; Girard L; Moran C; Hong WK; Minna JD; Wistuba II
    PLoS One; 2010 Feb; 5(2):e9112. PubMed ID: 20161759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Putative stemness markers octamer-binding transcription factor 4, sex-determining region Y-box 2, and NANOG in non-small cell lung carcinoma: A clinicopathological association.
    Upadhyay VA; Shah KA; Makwana DP; Raval AP; Shah FD; Rawal RM
    J Cancer Res Ther; 2020; 16(4):804-810. PubMed ID: 32930122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphologic and clinicopathologic features of lung squamous cell carcinomas expressing Sox2.
    Brcic L; Sherer CK; Shuai Y; Hornick JL; Chirieac LR; Dacic S
    Am J Clin Pathol; 2012 Nov; 138(5):712-8. PubMed ID: 23086772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
    Bourguignon LY; Wong G; Earle C; Chen L
    J Biol Chem; 2012 Sep; 287(39):32800-24. PubMed ID: 22847005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOX2 amplification is a common event in squamous cell carcinomas of different organ sites.
    Maier S; Wilbertz T; Braun M; Scheble V; Reischl M; Mikut R; Menon R; Nikolov P; Petersen K; Beschorner C; Moch H; Kakies C; Protzel C; Bauer J; Soltermann A; Fend F; Staebler A; Lengerke C; Perner S
    Hum Pathol; 2011 Aug; 42(8):1078-88. PubMed ID: 21334718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer.
    Wilbertz T; Wagner P; Petersen K; Stiedl AC; Scheble VJ; Maier S; Reischl M; Mikut R; Altorki NK; Moch H; Fend F; Staebler A; Bass AJ; Meyerson M; Rubin MA; Soltermann A; Lengerke C; Perner S
    Mod Pathol; 2011 Jul; 24(7):944-53. PubMed ID: 21460799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas.
    Watanabe H; Ma Q; Peng S; Adelmant G; Swain D; Song W; Fox C; Francis JM; Pedamallu CS; DeLuca DS; Brooks AN; Wang S; Que J; Rustgi AK; Wong KK; Ligon KL; Liu XS; Marto JA; Meyerson M; Bass AJ
    J Clin Invest; 2014 Apr; 124(4):1636-45. PubMed ID: 24590290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of stem cell-related marker expression and its correlation with histologic subtypes in lung adenocarcinoma.
    Park E; Park SY; Sun PL; Jin Y; Kim JE; Jheon S; Kim K; Lee CT; Kim H; Chung JH
    Oncotarget; 2016 Jul; 7(27):42502-42512. PubMed ID: 27285762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex-Determining Region Y-box 2 Promotes Growth of Lung Squamous Cell Carcinoma and Directly Targets Cyclin D1.
    Li C; He B; Huang C; Yang H; Cao L; Huang J; Hu C
    DNA Cell Biol; 2017 Apr; 36(4):264-272. PubMed ID: 28151013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma.
    Roudi R; Madjd Z; Ebrahimi M; Najafi A; Korourian A; Shariftabrizi A; Samadikuchaksaraei A
    Tumour Biol; 2016 Sep; 37(9):11843-11859. PubMed ID: 27048287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of OCT4, SOX2, and NANOG expression with oral squamous cell carcinoma progression.
    Fu TY; Hsieh IC; Cheng JT; Tsai MH; Hou YY; Lee JH; Liou HH; Huang SF; Chen HC; Yen LM; Tseng HH; Ger LP
    J Oral Pathol Med; 2016 Feb; 45(2):89-95. PubMed ID: 26211876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma.
    Lengerke C; Fehm T; Kurth R; Neubauer H; Scheble V; Müller F; Schneider F; Petersen K; Wallwiener D; Kanz L; Fend F; Perner S; Bareiss PM; Staebler A
    BMC Cancer; 2011 Jan; 11():42. PubMed ID: 21276239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex determining region Y-box 2 (SOX2) amplification is an independent indicator of disease recurrence in sinonasal cancer.
    Schröck A; Göke F; Wagner P; Bode M; Franzen A; Braun M; Huss S; Agaimy A; Ihrler S; Menon R; Kirsten R; Kristiansen G; Bootz F; Lengerke C; Perner S
    PLoS One; 2013; 8(3):e59201. PubMed ID: 23544055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis.
    Tang X; Kadara H; Behrens C; Liu DD; Xiao Y; Rice D; Gazdar AF; Fujimoto J; Moran C; Varella-Garcia M; Lee JJ; Hong WK; Wistuba II
    Clin Cancer Res; 2011 Apr; 17(8):2434-43. PubMed ID: 21257719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.
    Bass AJ; Watanabe H; Mermel CH; Yu S; Perner S; Verhaak RG; Kim SY; Wardwell L; Tamayo P; Gat-Viks I; Ramos AH; Woo MS; Weir BA; Getz G; Beroukhim R; O'Kelly M; Dutt A; Rozenblatt-Rosen O; Dziunycz P; Komisarof J; Chirieac LR; Lafargue CJ; Scheble V; Wilbertz T; Ma C; Rao S; Nakagawa H; Stairs DB; Lin L; Giordano TJ; Wagner P; Minna JD; Gazdar AF; Zhu CQ; Brose MS; Cecconello I; Ribeiro U; Marie SK; Dahl O; Shivdasani RA; Tsao MS; Rubin MA; Wong KK; Regev A; Hahn WC; Beer DG; Rustgi AK; Meyerson M
    Nat Genet; 2009 Nov; 41(11):1238-42. PubMed ID: 19801978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of SOX2, NANOG and OCT4 in a mouse model of lipopolysaccharide-induced acute uterine injury and intrauterine adhesions.
    Xiao L; Song Y; Huang W; Yang S; Fu J; Feng X; Zhou M
    Reprod Biol Endocrinol; 2017 Mar; 15(1):14. PubMed ID: 28253866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative Expression of OCT4, SOX2 and NANOG in Oral Squamous Cell Carcinoma Versus Adjacent Non- Tumor Tissue.
    Baghai Naini F; Aminishakib P; Abdollahi A; Hodjat M; Mohammadpour H; Kardouni Khoozestani N
    Asian Pac J Cancer Prev; 2019 Jun; 20(6):1649-1654. PubMed ID: 31244283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung adenocarcinoma resistance to therapy with EGFR‑tyrosine kinase inhibitors is related to increased expression of cancer stem cell markers SOX2, OCT4 and NANOG.
    Hu F; Li C; Zheng X; Zhang H; Shen Y; Zhou L; Yang X; Han B; Zhang X
    Oncol Rep; 2020 Feb; 43(2):727-735. PubMed ID: 31894290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of a putative tumor suppressor BMP4 by SOX2 promotes growth of lung squamous cell carcinoma.
    Fang WT; Fan CC; Li SM; Jang TH; Lin HP; Shih NY; Chen CH; Wang TY; Huang SF; Lee AY; Liu YL; Tsai FY; Huang CT; Yang SJ; Yen LJ; Chuu CP; Chen CY; Hsiung CA; Chang JY; Wang LH; Chang IS; Jiang SS
    Int J Cancer; 2014 Aug; 135(4):809-19. PubMed ID: 24477565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines.
    Wang P; Gao Q; Suo Z; Munthe E; Solberg S; Ma L; Wang M; Westerdaal NA; Kvalheim G; Gaudernack G
    PLoS One; 2013; 8(3):e57020. PubMed ID: 23469181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.